Literature DB >> 3757184

Risk stratification for 1 year survival based on characteristics identified in the early hours of acute myocardial infarction. The Western Washington Intracoronary Streptokinase Trial.

M L Stadius, K Davis, C Maynard, J L Ritchie, J W Kennedy.   

Abstract

We evaluated the relationship between baseline factors defined at 4.6 +/- 2.1 hr after onset of acute myocardial infarction and 1 year survival in 245 patients entered in the Western Washington Intracoronary Streptokinase Trial. Univariate statistics identified a significant relationship between 10 of these factors and survival. Multivariate analysis identified three factors as being most closely related to survival: (1) left ventricular ejection fraction (LVEF) (p less than .0001), (2) treatment with streptokinase (p = .03), and (3) location of infarction (p = .04). Mathematic models based on this analysis and applied to our patients identified high- and low-risk subgroups for 1 year mortality. Patients receiving standard, not interventional, therapy with anterior infarction and an LVEF of 50% or less and those with inferior infarction and an LVEF of 39% or less comprised the high-risk group. For patients receiving standard therapy, 1 year mortality was 41% in the high-risk group and 4% in the low-risk group. The models illustrated the magnitude of benefit of streptokinase treatment and achievement of complete reperfusion for those at low and high risk. We conclude that LVEF determined in the first hours of acute myocardial infarction is the most important of all baseline factors for prediction of 1 year survival. Mathematic models based on left ventricular function measured as ejection fraction are useful for risk stratification in this setting.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3757184     DOI: 10.1161/01.cir.74.4.703

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

1.  Time to Reperfusion: The Critical Modulator in Thrombolysis and Primary Angioplasty.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

2.  Assessment of reperfusion after acute myocardial infarction: is there a role for acute technetium 99m-teboroxime imaging?

Authors:  A J Sinusas
Journal:  J Nucl Cardiol       Date:  1996 Jan-Feb       Impact factor: 5.952

Review 3.  Prognostic assessment in coronary artery disease: role of radionuclide angiography.

Authors:  R O Bonow
Journal:  J Nucl Cardiol       Date:  1994 May-Jun       Impact factor: 5.952

4.  Recovery of Left Ventricular Systolic Function and Clinical Outcomes in Young Adults With Myocardial Infarction.

Authors:  Wanda Y Wu; David W Biery; Avinainder Singh; Sanjay Divakaran; Adam N Berman; Gloria Ayuba; Ersilia M DeFilippis; Khurram Nasir; James L Januzzi; Marcelo F Di Carli; Deepak L Bhatt; Ron Blankstein
Journal:  J Am Coll Cardiol       Date:  2020-06-09       Impact factor: 24.094

5.  Time to Treatment: A Crucial Factor in Thrombolysis and Primary Angioplasty.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

6.  The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. For the CORE investigators (Collaborative Organisation for RheothRx Evaluation).

Authors:  P Chareonthaitawee; R J Gibbons; R S Roberts; T F Christian; R Burns; S Yusuf
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

Review 7.  Prehospital thrombolysis: an idea whose time has come.

Authors:  C P Cannon; A J Sayah; R M Walls
Journal:  Clin Cardiol       Date:  1999-08       Impact factor: 2.882

8.  Early prediction of improvement in ejection fraction after acute myocardial infarction using low dose dobutamine echocardiography.

Authors:  F Nijland; O Kamp; P M J Verhorst; W G de Voogt; C A Visser
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

9.  Patency of the infarct-related coronary artery--a pertinent factor in late recovery of myocardial fatty acid metabolism among patients receiving thrombolytic therapy?

Authors:  M Walamies; V Virtanen; M Koskinen; A Uusitalo
Journal:  Eur J Nucl Med       Date:  1994-09

10.  After thrombolytic therapy: angiography, angioplasty, or surgery?

Authors:  M L Stadius
Journal:  Tex Heart Inst J       Date:  1990
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.